Anti-inflammatory effect of glucose-lysine Maillard reaction products on intestinal inflammation model in vivo

Chung Oui Hong, Chae Hong Rhee, Min Cheol Pyo, Kwang Won Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.

Original languageEnglish
Pages (from-to)324-332
Number of pages9
JournalInternational Immunopharmacology
Volume52
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Maillard Reaction
Lysine
Anti-Inflammatory Agents
Inflammation
Colon
Glucose
Dextran Sulfate
Colitis
Inflammatory Bowel Diseases
Muramidase
Glutathione Peroxidase
Serum
Drinking Water
Catalase
Lipid Peroxidation
Peroxidase
Superoxide Dismutase
Glutathione
Weight Loss
Nitric Oxide

Keywords

  • Colitis
  • Cytokines
  • Dextran sulfate sodium
  • Inflammatory bowel diseases
  • Maillard reaction products

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Anti-inflammatory effect of glucose-lysine Maillard reaction products on intestinal inflammation model in vivo. / Hong, Chung Oui; Rhee, Chae Hong; Pyo, Min Cheol; Lee, Kwang Won.

In: International Immunopharmacology, Vol. 52, 01.11.2017, p. 324-332.

Research output: Contribution to journalArticle

@article{b24bc9aef1a947fb94c6e5a7b4668a45,
title = "Anti-inflammatory effect of glucose-lysine Maillard reaction products on intestinal inflammation model in vivo",
abstract = "Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5{\%} dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.",
keywords = "Colitis, Cytokines, Dextran sulfate sodium, Inflammatory bowel diseases, Maillard reaction products",
author = "Hong, {Chung Oui} and Rhee, {Chae Hong} and Pyo, {Min Cheol} and Lee, {Kwang Won}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.intimp.2017.09.009",
language = "English",
volume = "52",
pages = "324--332",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anti-inflammatory effect of glucose-lysine Maillard reaction products on intestinal inflammation model in vivo

AU - Hong, Chung Oui

AU - Rhee, Chae Hong

AU - Pyo, Min Cheol

AU - Lee, Kwang Won

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.

AB - Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.

KW - Colitis

KW - Cytokines

KW - Dextran sulfate sodium

KW - Inflammatory bowel diseases

KW - Maillard reaction products

UR - http://www.scopus.com/inward/record.url?scp=85030451746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030451746&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2017.09.009

DO - 10.1016/j.intimp.2017.09.009

M3 - Article

VL - 52

SP - 324

EP - 332

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

ER -